(Q43052119)

13 November 2017

Role of Engrailed-2 (EN2) as a prostate cancer detection biomarker in genetically high risk men. (English)

1 reference

13 November 2017

0 references

9

1 reference

13 November 2017

14

1 reference

13 November 2017

18

1 reference

13 November 2017

24

1 reference

13 November 2017

Richard Morgan

2

0 references

Elena Castro

object named as

Elena Castro

6

0 references

Susan M Domchek

11

object named as

Susan Domchek

1 reference

13 November 2017

13

Diana Eccles

1 reference

13 November 2017

7

Zsofia Kote-Jarai

1 reference

13 November 2017

Emma Killick

1

1 reference

13 November 2017

Francesca Launchbury

3

1 reference

13 November 2017

Elizabeth Bancroft

4

1 reference

13 November 2017

Elizabeth Page

5

1 reference

13 November 2017

Armen Aprikian

8

1 reference

13 November 2017

Virginia Clowes

10

1 reference

13 November 2017

Fiona Douglas

12

1 reference

13 November 2017

Marion Harris

15

1 reference

13 November 2017

Judy Kirk

16

1 reference

13 November 2017

Jimmy Lam

17

1 reference

13 November 2017

Gillian Mitchell

19

1 reference

13 November 2017

Nicholas Pachter

20

1 reference

13 November 2017

Christina Selkirk

21

1 reference

13 November 2017

Kathy Tucker

22

1 reference

13 November 2017

Janaz Zgajnar

23

1 reference

13 November 2017

Hardev Pandha

25

1 reference

13 November 2017

language of work or name

English

0 references

publication date

1 January 2013

1 reference

13 November 2017

1 reference

13 November 2017

3

1 reference

13 November 2017

2059

1 reference

Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported

13 November 2017

start time

24 June 2013

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Urinary engrailed-2 (EN2) levels predict tumour volume in men undergoing radical prostatectomy for prostate cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3690389

Germline BRCA1 mutations increase prostate cancer risk

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3690389

26 May 2018

Cancer statistics, 2012

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3690389

BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3690389

BRCA1 mutations do not increase prostate cancer risk: results from a meta-analysis including new data

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3690389

Engrailed-2 (EN2): a tumor specific urinary biomarker for the early diagnosis of prostate cancer

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3690389

Current perspectives on the Gleason grading of prostate cancer

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3690389

Screening and prostate-cancer mortality in a randomized European study

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3690389

Mortality results from a randomized prostate-cancer screening trial

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3690389

Prostate cancer in male BRCA1 and BRCA2 mutation carriers has a more aggressive phenotype

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3690389

Prostate cancer risk with positive family history, normal prostate examination findings, and PSA less than 4.0 ng/mL.

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3690389

EN2 is a candidate oncogene in human breast cancer

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3690389

Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3690389

Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3690389

Genetic variants associated with predisposition to prostate cancer and potential clinical implications

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3690389

The role of a standardized 36 core template-assisted transperineal prostate biopsy technique in patients with previously negative transrectal ultrasonography-guided prostate biopsies

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3690389

Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3690389

The sextant protocol for ultrasound-guided core biopsies of the prostate underestimates the presence of cancer

16 August 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23792811

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Nonpalpable stage T1c prostate cancer: prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23792811

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23792811

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/SREP02059

1 reference

13 November 2017

1 reference

13 November 2017

PubMed publication ID

23792811

1 reference